CSL Seqirus' cell-based quadrivalent flu vaccine, Flucelvax QUAD, is now available on the National Immunisation Program for the first time to protect at-risk Australians from influenza. …
At-risk Australians now have funded access to CSL Seqirus' cell-based flu vaccine
April 3, 2024 Latest NewsBioPharma
Latest Video
New Stories
-
Vaccine confidence slips as Australians grow more concerned about access to healthcare
October 20, 2025 - - Latest News -
NZ's Pharmac proposes new rules to manage 'Options for Investment' list
October 20, 2025 - - Latest News -
Monash scientists crack genetic ‘code’ behind RNA splicing, opening door to to new therapies
October 20, 2025 - - Australian Biotech -
Radiopharm secures funding to accelerate radiopharmaceutical pipeline as data show strong momentum
October 20, 2025 - - Australian Biotech -
Neuren secures FDA 'Fast Track Designation' for NNZ-2591 in Phelan-McDermid Syndrome
October 20, 2025 - - Australian Biotech -
Biogen earns fourth 'Great Place to Work' certification, strengthening culture of inclusion
October 20, 2025 - - Latest News -
Algorae partners with Cadila Pharmaceuticals to launch therapies in Australia and New Zealand
October 20, 2025 - - Latest News